Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Grifols, S.A.NASDAQ: GRFS

Effect of Forex Changes · Q2 FY2026 · quarter ended Jun 2026

Effect of forex changes turns positive

Q2 FY2026 effect of forex changes was €7M, compared with -€60.34M a year earlier. Trailing-twelve-month effect of forex changes was €5.96M. Over 3 fiscal years it compounded at -17.8% a year.

Context

  • Effect of forex changes amounted to 0.3% of revenue in FY2025, unchanged from a year earlier.
  • Effect of forex changes increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly effect of forex changes holds near €7M or moves back toward the trailing-twelve-month quarterly average of €1.49M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
€7M+486.8% QoQ
Last fiscal yearDec 2025
€19.75M-1.7% YoY
LTMJun 2026
€5.96M+107.3% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+111.6%——
1 year-1.7%——
3-year CAGR-17.8%——
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

EUR · from the cash flow

Latest · FY2025
19.75M EUR
Year-over-year change
-1.7%
4-year CAGR
-22.8%

Effect of Forex Changes vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +107.3% is the 5th highest of 8, against a peer median of +168.0%.
  • Effect of forex changes amounts to 0.1% of revenue for GRFS, versus a peer median of 0.1%.
GRFS Competitors
Effect of Forex Changes for GRFS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BDXBecton, Dickinson and CompanyLTM Sep 2026$79M USD+8000.0%+11.9%0.4%
ABTAbbott LaboratoriesLTM Jun 2026$23M USD-182.1%—0.0%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$10.4M USD+168.0%—0.4%
GRFSGrifols, S.A.LTM Jun 2026€5.96M EUR+107.3%-17.8%0.1%
HAEHaemonetics CorporationLTM Jun 2026$1.34M USD-127.0%—0.1%
QDELQuidelOrtho CorporationLTM Mar 2026$1.3M USD+1400.0%—0.0%
TECHBio-Techne CorporationLTM Sep 2026$1.28M USD-122.8%-12.6%0.1%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$53K USD+239.5%—0.0%
ADMAADMA Biologics, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding GRFS) —+168.0%-0.3%0.1%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income188.73M361.26M207.02M444M386.13M
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital(181.36M)(609.22M)(362.84M)22.38M(24.01M)
Accounts Receivables(16.81M)(80.17M)(68.82M)(41.88M)(30.74M)
Inventory(157.47M)(600.25M)(411.44M)25.82M(93.17M)
Accounts Payables080.21M0090.29M
Other Working Capital(7.08M)(9.01M)117.41M38.44M9.61M
Other Non-Cash Items229.84M(173.89M)(71.91M)(2.1M)211.32M
Operating Cash Flow596.98M(10.87M)218.69M902.17M1.01B
Capital Expenditures(247.37M)(375.56M)(310.32M)(371.37M)(254.54M)
Acquisitions (Net)(519.13M)(1.44B)(29.47M)(285.87M)(99.9M)
Purchases of Investments0(164.66M)(93.31M)(43.85M)(54.75M)
Sales of Investments0015.14M04.8M
Other Investing Activities(87.65M)3.28M(62.64M)1.45B0
Investing Cash Flow(854.15M)(1.98B)(394.72M)886.67M(556.15M)
Debt Repayment2.75B(104.29M)(116.39M)(111.49M)(119M)
Common Stock Issued00000
Common Stock Repurchased(125.7M)(3.46M)00(123.91M)
Dividends Paid(252.44M)(592K)0(962K)(122.95M)
Other Financing Activities(70.56M)(65.16M)287.89M(1.25B)(142.26M)
Financing Cash Flow2.3B(173.49M)171.49M(1.36B)(508.12M)
Effect of Forex Changes55.46M35.55M(15.09M)20.08M19.75M
Net Change in Cash2.1B(2.13B)(19.63M)450.2M(38.85M)
Free Cash Flow349.6M(386.43M)(91.63M)530.8M751.14M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.